Mednet Logo
SpecialtiesGynecologic Oncology
Gynecologic Oncology

Gynecologic Oncology

Clinical discussions on gynecologic malignancies, surgical approaches, and multimodal treatment strategies.

Recent Discussions

What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?

8
3 Answers

Mednet Member
Mednet Member
Geriatric Medicine · Case Western Reserve University/University Hospitals Cleveland Medical Center

Hope for the miracle yourself! Broaden: “Are there any other things you are hoping for?” Hope for the best, prepare for the worst: “I see how much you want a miracle. I wonder if we can talk about what we should do if this doesn’t happen.” Consider involving a religious leader if relevant.

What is your current practice for obtaining mutation status for a patient with newly diagnosed ovarian cancer?

3 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Center of Hope

My current practice is to test all newly diagnosed epithelial ovarian cancer patients (includes fallopian tube and peritoneal) with both germline multigene and somatic multigene/NGS panels. Only recently have I adopted the practice of concurrent testing at diagnosis rather than basing the decision t...

How should you manage a COVID-19 infected/suspected patient who is receiving chemotherapy and cannot interrupt or delay their cancer treatment?

8
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Fred Hutchinson Cancer Research Center

This is difficult to answer specifically without further details. There certainly is accumulating evidence that patients with cancer, especially those receiving immunosuppressive chemotherapy, are at greater risk of COVID-19 infection if exposed, and a greater risk of serious and life-threatening co...

If a patient meets criteria for extrafascial hysterectomy for early-stage cervical cancer, how do you determine your surgical approach (abdominal vs laparoscopic)?

3 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · University of California Irvine Medical Center

For FIGO 1A1-1A2 (i.e., microinvasion which means no visible lesion) - I would perform a vaginal hysterectomy with bilateral salpingectomy (IA1) or robotic hysterectomy with bilateral salpingectomy-nodes (IA2); for FIGO 1B1 with no visible lesion (eg., post-conization), I would perform a robotic cys...

When do you recommend PD-L1 testing for patients with recurrent cervical cancer?

1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · University of California Irvine Medical Center

I think getting the testing done as soon as possible is best because very few patients will only need first line therapy. This way, there is less of a delay at the time of progression following/during first-line therapy.

Do you recommend frontline bevacizumab with carbo/taxol in patients with advanced epithelial ovarian and BRCA mutation who will be receiving olaparib maintenance?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Harvard Medical School

As shown in GOG-218, there is no apparent benefit to using concurrent bevacizumab with paclitaxel and carboplatin in the first-line setting, if this drug is not then continued during maintenance therapy. Our approach is to obtain genetic testing in patients with epithelial ovarian cancer as soon as ...

What adjuvant therapy do you recommend, if any, for a vaginal margin that is positive for HSIL/VAIN3 following radical hysterectomy but negative for invasive cancer and otherwise does not meet Sedlis criteria for adjuvant radiation?

1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · Cooper Medical School of Rowan University

I usually perform standard surveillance for cervical cancer recurrence with exams, review of symptoms, and at least yearly pap as outlined by the NCCN. If the surveillance pap shows HSIL, then I perform colposcopy and treat and detect VAIN according to biopsy results.

Are you altering your use of immune checkpoint inhibitors given the risk of immune-related pneumonitis and the COVID-19 outbreak?

1
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Vanderbilt-Ingram Cancer Center

The management of advanced cancer patients has gotten even more complex with the COVID-19 pandemic. In general, providers are trying to keep patients away from the hospital/clinic as much as possible, and avoiding regimens with greater toxicity if there are suitable less toxic alternatives. Whether ...

What is your radiotherapy plan for stage IVA (cT4) cervical SCC with the tumor completely obliterating the bladder trigone?

4
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I would follow the same schedule. After concurrent chemo RT, I would use HDR brachy with a hybrid applicator to achieve a D90 of 85 Gy or above to the HR-CTV and avoid any hotspot in the bladder wall. Part of the bladder wall in the trigone area receives a therapeutic dose.

Are there scenarios that new visits/consults with patients can be done virtually amidst the COVID-19 outbreak?

6
6 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic Rochester

Starting 3/16, we began offering lower-complexity / lower-risk patients the option of having a Tele-medicine consult vs re-scheduling to a later date. This offer has been extended broadly to all new consults at our facility when the provider indicates that s/he can extend comparable service virtuall...